Expanding Biomedical Portfolio Cuprina's recent expansion into biomedical products for chronic wounds, infertility, and cosmeceuticals presents significant cross-selling opportunities with healthcare providers, clinics, and hospitals seeking innovative treatment solutions.

Regional Supply Capabilities With the successful setup of manufacturing labs and exclusive licensing in the Middle East and North Africa, Cuprina is positioned to supply advanced wound care therapies directly to regional markets, opening opportunities for distributors and healthcare distributors.

Regulatory Progress Cuprina's achievement in obtaining ISO 13485 certification and relevant licenses for its IVF media and wound therapy products underscores its readiness to enter and scale within regulated markets, providing a compelling case for partnerships with healthcare agencies and medical supply companies.

Innovation and R&D Ongoing research collaborations aimed at deriving collagen peptides from frog skin and developing maggot debridement therapy highlight Cuprina's focus on cutting-edge solutions, which can attract interest from investors and partners in biotech and advanced wound care sectors.

Market Growth Potential With a strong revenue range of 500 million to one billion dollars and recent successful IPO fundraising, Cuprina's financial strength and growth trajectory make it an attractive partner for pharmaceutical firms, medical device companies, and regional distributors seeking to expand their product offerings.